Dry Eye Syndrome Treatment Market: By Treatment Type (Lubricant Eye Drops, Anti-inflammatory Drugs, Surgery) & By Geography (Europe, Asia Pacific, North America, Rest of the World)-Forecast (2016-2021)

  • ID: 3973919
  • Report
  • Region: Global, America, Asia, Asia Pacific, Europe, North America, United States
  • 155 pages
  • IndustryARC
1 of 4


  • Allergan Inc.
  • Dong-A ST Co., Ltd.
  • Merck Sharp & Dohme Corp.
  • Novartis A.G
  • Otsuka Holdings Co.Ltd
  • Shire
  • MORE
Eyes secrete fluid continuously, also known as tear film, which cover the eyes and remain stable between each blink and prevent the eyes from becoming dry. This tear film keeps the eyes clear with stress-free vision. Dry eye syndrome is a disease in which there is high tear film evaporation or low tear production thus eye is unable to maintain a healthy coating of tears. So, a healthy tear film on the eye is essential for good vision.
Population affected with dry eye syndrome is increasing because of many underlying causes of the disease. It is more frequent in old age; young generation is also affected by the disease because of change in lifestyle, poor dietary intake, more habituated towards mobiles and laptops, frequent travelling and rising pollution levels. Malnutrition resulting from vitamin A deficiency is also common cause of dry eye syndrome in some parts of the world. Other common causes include dry environment or workplace, medication, complications arising from eye surgeries and as a result of autoimmune disorders.
Dry eye syndrome treatment can be done by knowing the underlying cause of disease. Various methods include lubricant treatments, anti-inflammatory treatments, autologous serum eye drops and surgery etc.
There are various key factors driving the growth of dry eye syndrome treatment market like increasing prevalence of the disease, increasing awareness about the disease, demand for better treatment options, impact of other diseases like Diabetes, Sjogren's syndrome, Vitamin A deficiency, Lupus scleroderma and Rheumatoid arthritis. Other drivers include focus towards development of novel technologies and contribution of non-governmental organizations towards the disease.
This report provides information on dry eye syndrome treatment market size for the year 2014-2016, and forecast of the same for year 2021. It also focuses on market drivers, challenges, restraints, market dynamics, growth indicators, competitive landscape, potential growth opportunities and other key aspects with respect to dry eye syndrome.

The prevalence of the disease is high in APAC region compared to USA and Europe. China and India are potential markets for dry eye syndrome due to high prevalence of the disease, growth in the market for the disease is expected due to growing population, environmental factors and lack of awareness. USA and Europe have better treatment options and high awareness about the disease and they remain good market for dry eye syndrome.
This report of dry eye syndrome treatment market is segregated on the basis of treatment type and regional market as follows:
Dry eye syndrome treatment market is segmented based on the available treatments which include major treatment namely: Lubricant Eye Drops, Anti-inflammatory Drugs, autologous Serum Eye Drops and surgery

This report has been further segmented into major regions, which include detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report looks into all the major companies operating in the dry eye syndrome treatment. Some of the key market players in global dry eye syndrome treatment market are:
Novartis AG
Allergan Inc.
Otsuka Holdings Co. Ltd.
Santen Pharmaceutical Co. Ltd.
Bausch & Lomb Incorporated
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 4


  • Allergan Inc.
  • Dong-A ST Co., Ltd.
  • Merck Sharp & Dohme Corp.
  • Novartis A.G
  • Otsuka Holdings Co.Ltd
  • Shire
  • MORE
1. Dry Eye Syndrome Treatment - Market Overview
2. Executive Summary
3. Dry Eye Syndrome Treatment - Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Dry Eye Syndrome Treatment - Market Forces
4.1. Drivers
4.1.1. Prevalence of the disease in APAC
4.2. Restraints
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Customers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Dry Eye Syndrome Treatment Market - Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Dry Eye Syndrome Treatment Market, By Treatment type
6.1. Lubricant Eye Drops
6.2. Anti-inflammatory Drugs
6.3. Surgery
6.4. Others
7. Dry Eye Syndrome Treatment Market, By Geography
7.1. Introduction
7.2. North America
7.2.1. US
7.2.2. Canada
7.2.3. Mexico
7.3. Europe
7.3.1. U.K
7.3.2. France
7.3.3. Germany
7.3.4. Italy
7.3.5. Spain
7.3.6. Rest of Europe
7.4. Asia Pacific
7.4.1. China
7.4.2. South Korea
7.4.3. Japan
7.4.4. India
7.4.5. Rest of Asia Pacific
7.5. RoW
8. Market Entropy
8.1. Expansion
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply - Contract
9. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
9.1. Novartis A.G
9.2. Allergan Inc.
9.3. Otsuka Holdings Co.Ltd
9.4. Santen Pharmaceutical Co.Ltd
9.5. Bausch & Lomb Incorporated
9.6. Merck Sharp & Dohme Corp.
9.7. Shire
9.8. Kissei Pharmaceutical Co., Ltd.
9.9. Dong-A ST Co., Ltd.
9.10. Kissei Pharmaceutical Co., Ltd.
  • More than 40 Companies are profiled in this Research Report, Complete List available on Request -
" - Financials would be provided on a best efforts basis for private companies"
10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Novartis A.G
Allergan Inc.
Otsuka Holdings Co.Ltd
Santen Pharmaceutical Co.Ltd
Bausch & Lomb Incorporated
Merck Sharp & Dohme Corp.
Kissei Pharmaceutical Co., Ltd.
Dong-A ST Co., Ltd.
Kissei Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown